SCHEMBL260490

SCHEMBL260490

Cc1cccc(Oc2ccc(CO)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.63
ALDH1A1 P00352 2/20 0.61
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
FFAR1 O14842 3/20 0.50
HSD17B1 P14061 1/20 0.49
HSD17B2 P37059 1/20 0.49
ACHE P22303 1/20 0.47
GFER P55789 2/20 0.46
MAPK1 P28482 1/20 0.46
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
AR P10275 2/20 0.45
GAA P10253 1/20 0.45
TTR P02766 1/20 0.45
SLC5A2 P31639 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30979256 0.87 ALDH1A1 (0.53) LTA4HALDH1A1HTTTDP1L3MBTL1
SCHEMBL1747441 0.87 ALDH1A1 (0.53) LTA4HALDH1A1HTTTDP1L3MBTL1
SCHEMBL9889449 0.86 ALDH1A1 (0.57) LTA4HALDH1A1HTTTDP1L3MBTL1
SCHEMBL14159532 0.85 ALDH1A1 (0.65) ALDH1A1HTTTDP1L3MBTL1FFAR1
SCHEMBL10013918 0.85 ALDH1A1 (0.65) ALDH1A1HTTTDP1L3MBTL1FFAR1
SCHEMBL10013917 0.84 ALDH1A1 (0.80) ALDH1A1HTTTDP1L3MBTL1HSD17B1
SCHEMBL14159539 0.84 ALDH1A1 (0.80) ALDH1A1HTTTDP1L3MBTL1HSD17B1
SCHEMBL506995 0.84 ALDH1A1 (0.68) ALDH1A1HTTTDP1L3MBTL1FFAR1
SCHEMBL170709 0.84 ALDH1A1 (0.62) ALDH1A1HTTTDP1L3MBTL1FFAR1
SCHEMBL15831788 0.83 LTA4H (0.84) LTA4HALDH1A1HTTFFAR1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-8067440-B2 Phosphonium salts derivatives and uses thereof VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2011-11-29 US disclosed
US-20110092683-A1 PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS PLA2G7, PLA2G4A, PLA2G1B LTA4H 24/4885ALDH1A1 1690/4885HTT 1537/4885
US-20110092683-A1 PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF PI4K2A, PIP4K2A, PI4K2B LTA4H 3488/4885ALDH1A1 3468/4885HTT 4683/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 LTA4H 44/4885ALDH1A1 2825/4885HTT 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.